Vanda Pharmaceuticals Inc (NASDAQ:VNDA)

10.10
Delayed Data
As of May 28
 -0.05 / -0.49%
Today’s Change
8.34
Today|||52-Week Range
16.50
-29.47%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$424.3M

Company Description

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. Its product portfolio includes Fanapt and Tasimelteon. The Fanapt product is a compound for the treatment of schizophrenia, the oral formulation of, which is currently being marketed and sold in the U.S. by Novartis. The Tasimelteon product is a compound for the treatment of sleep and mood disorders, including circadian rhythm sleep disorders, which is currently in clinical development. Vanda Pharmaceuticals was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Contact Information

Vanda Pharmaceuticals, Inc.
2200 Pennsylvania Avenue NW
Washington District Of Columbia 20037
P:(202) 734-3400
Investor Relations:
(202) 734-3428

Employees

Shareholders

Other institutional68.42%
Mutual fund holders45.33%
Individual stakeholders41.32%

Top Executives

Mihael Hristos PolymeropoulosPresident, Chief Executive Officer & Director
James Patrick KellyCFO, Secretary, Treasurer & Senior Vice President
Paolo BaroldiChief Medical Officer & Senior Vice President
Thomas GibbsChief Commercial Officer & Senior Vice President
Gunther BirznieksVice President-Business Development

To view my watchlist

Not a member yet?

Sign up now for a free account